Research Spotlight: Innovative Nanovaccine Found to Trigger an Anti-Tumor Response for Rare Cancer
Researchers used a nanovaccine to trigger an anti-tumor response for a rare form of melanoma.
Research at Massachusetts General Hospital includes multitude of hospital-wide centers, institutes and programs as well as collaborations with other institutions.
Researchers used a nanovaccine to trigger an anti-tumor response for a rare form of melanoma.
Caitlin Dugdale, MD, MSc, and Kimon Zachary, MD, are co-lead authors of a new study in Infection Control and Hospital Epidemiology, TB or Not TB? Development and Validation of a Clinical Decision Support System for the Evaluation of Suspected Tuberculosis.
Researchers used computer modeling to evaluate the potential clinical impact and cost-effectiveness of administering long-acting, injectable antibodies to infants from birth to prevent HIV infection during breastfeeding.
Given uncertainties about future PEPFAR funding, researchers modeled the impact of abrupt PEPFAR cutbacks in South Africa
Write a short description of the Research Spotlight.
Researchers demonstrated that a new imaging technique can yield quantitative estimates of baseline tumor PD-L1 heterogeneity lab models.
Researchers used a nanovaccine to trigger an anti-tumor response for a rare form of melanoma.
Caitlin Dugdale, MD, MSc, and Kimon Zachary, MD, are co-lead authors of a new study in Infection Control and Hospital Epidemiology, TB or Not TB? Development and Validation of a Clinical Decision Support System for the Evaluation of Suspected Tuberculosis.
Researchers used computer modeling to evaluate the potential clinical impact and cost-effectiveness of administering long-acting, injectable antibodies to infants from birth to prevent HIV infection during breastfeeding.
Given uncertainties about future PEPFAR funding, researchers modeled the impact of abrupt PEPFAR cutbacks in South Africa